Codelivery of DTXL and GRP78 siRNA enhances the anti-prostate cancer effects in vitro and in vivo and sensitizes the cell-killing effect of DTXL. This method may be especially useful for treating drug-resistant CRPC. The gene discussed is HSPA5; the disease is prostate carcinoma.